CalciMedica, Inc. Common Stock
Here’s whether CalciMedica, Inc. Common Stock (CALC) is worth buying in 2026 — based on weekly-updated price trend, RSI momentum, and return vs. the S&P 500. Our current read: Caution.
Positives: above the 50-day MA (medium-term momentum positive); 50-day MA is rising (+3.02% over 10 days); 3-month momentum positive (+45.0%). Concerns: trading below the 200-day MA (long-term downtrend); RSI 77 — overbought, elevated pullback risk; weak 1-year return of -36.9%; rising volume on a downtrend (distribution, 1.95x avg). Currently 85.3% off its 52-week high. Score: -1/7.
CALC is trading below its 200-day MA ($2.46) — a key warning sign the longer-term trend is under pressure. With an RSI of 77.4, momentum has stretched into overbought territory — short-term pullbacks are common from these levels. The 1-year return of -36.9% compares to +24.4% for SPY (trailed the market by 61.3%). The current 85.3% drawdown from the 52-week high reflects elevated risk for momentum-based strategies.